Table 2. Meta-analysis results of all studies and each subgroup studies.

	Cases	Heterogeneity analysis		Pooled SMD	95% CI
		I2 (%)	P value
Variant genotype*	526	31	0.12	0.03	-0.07-0.13
China populations†	158	49	0.07	0.03	-0.15-0.21
Variant genotype (T/C)‡	284	63	0.02	0.06	-0.08-0.20
Variant genotype (C/C)§	22	0	0.41	-0.15	-0.57-0.28
Variant genotype (T/C & C/C)∥	220	0	0.55	0.01	-0.15-0.16

^*Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism; ^†Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism in Chinese populations; ^‡Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 variant heterozygotes (T/C); ^§Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 variant homozygotes (C/C); ^∥These studies did not provide the cases of single heterozygote (T/C) or homozygote (C/C).

Abbreviations: SMD, standard mean difference; CI, confidence interval.